Active surveillance versus treatment in low-risk DCIS: Women’s preferences in the LORD-trial
European Journal of Cancer · 2023-10 · 192 · 113276
DOI: 10.1016/j.ejca.2023.113276 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2023-10. Verfasst von Renée S J M Schmitz und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Intraductal, Noninfiltrating, Breast Neoplasms. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Ministerie van Volksgezondheid, Welzijn en Sport, KWF Kankerbestrijding.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Dutch Breast Cancer Society ('Borstkanker Vereniging Nederland'), Utrecht, the Netherlands.
- Department of Radiation Oncology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Förderung
- Cancer Research UK
- Ministerie van Volksgezondheid, Welzijn en Sport
- KWF Kankerbestrijding
- Pink Ribbon Foundation
Zitieren
APA
Schmitz, R. S. J. M., Engelhardt, E. G., Gerritsma, M. A., Sondermeijer, C. M. T., Verschuur, E., Houtzager, J., Griffioen, R., Retèl, V., Bijker, N., Mann, R. M., van Duijnhoven, F., Wesseling, J., Bleiker, E. M. A., & Grand Challenge PRECISION Consortium (2023). Active surveillance versus treatment in low-risk DCIS: Women’s preferences in the LORD-trial. European Journal of Cancer, 192, 113276. https://doi.org/10.1016/j.ejca.2023.113276
Vancouver
Schmitz RSJM, Engelhardt EG, Gerritsma MA, Sondermeijer CMT, Verschuur E, Houtzager J, et al. Active surveillance versus treatment in low-risk DCIS: Women’s preferences in the LORD-trial. European Journal of Cancer. 2023;192:113276. doi:10.1016/j.ejca.2023.113276
BibTeX
@article{Schmitz2023,
author = {Schmitz, Renée S J M and Engelhardt, Ellen G and Gerritsma, Miranda A and Sondermeijer, Carine M T and Verschuur, Ellen and Houtzager, Julia and Griffioen, Rosalie and Retèl, Valesca and Bijker, Nina and Mann, Ritse M and van Duijnhoven, Frederieke and Wesseling, Jelle and Bleiker, Eveline M A and Grand Challenge PRECISION Consortium, Grand Challenge PRECISION Consortium},
title = {Active surveillance versus treatment in low-risk DCIS: Women’s preferences in the LORD-trial},
journal = {European Journal of Cancer},
year = {2023},
volume = {192},
pages = {113276},
doi = {10.1016/j.ejca.2023.113276}
}
EUVIMED